Trexquant Investment LP grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) by 22.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 73,512 shares of the biotechnology company’s stock after buying an additional 13,359 shares during the period. Trexquant Investment LP’s holdings in BioCryst Pharmaceuticals were worth $778,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in BCRX. Diversified Trust Co increased its stake in shares of BioCryst Pharmaceuticals by 6.6% during the second quarter. Diversified Trust Co now owns 19,408 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 1,200 shares during the period. Semmax Financial Advisors Inc. increased its stake in shares of BioCryst Pharmaceuticals by 389.6% during the first quarter. Semmax Financial Advisors Inc. now owns 1,699 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,352 shares during the period. Arizona State Retirement System increased its stake in shares of BioCryst Pharmaceuticals by 2.9% during the second quarter. Arizona State Retirement System now owns 50,043 shares of the biotechnology company’s stock worth $529,000 after purchasing an additional 1,403 shares during the period. E Fund Management Co. Ltd. increased its stake in shares of BioCryst Pharmaceuticals by 11.8% during the first quarter. E Fund Management Co. Ltd. now owns 16,641 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 1,756 shares during the period. Finally, Fairfield Bush & CO. bought a new position in shares of BioCryst Pharmaceuticals during the first quarter worth approximately $34,000. 80.68% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
BCRX has been the topic of a number of recent research reports. Royal Bank of Canada lowered their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 2nd. Barclays raised their price objective on BioCryst Pharmaceuticals from $12.00 to $14.00 and gave the stock an “equal weight” rating in a research note on Friday, August 5th. StockNews.com assumed coverage on BioCryst Pharmaceuticals in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. Evercore ISI upgraded BioCryst Pharmaceuticals from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $14.00 to $16.00 in a research note on Wednesday, November 2nd. Finally, Oppenheimer lowered BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, August 5th. Six analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $17.00.
Insider Activity at BioCryst Pharmaceuticals
BioCryst Pharmaceuticals Stock Down 2.4 %
NASDAQ BCRX opened at $12.39 on Friday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $7.61 and a twelve month high of $19.99. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -11.80 and a beta of 2.00. The business’s fifty day moving average is $13.08 and its 200 day moving average is $12.03.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
- Get a free copy of the StockNews.com research report on BioCryst Pharmaceuticals (BCRX)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.